{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123314","form_type":"8-K","ticker":"CTMX","cik":"0001501989","company_name":"CytomX Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.611683+00:00","generated_at":"2026-05-30T03:29:29.859273+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance","bullets":["Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).","Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.","CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.","CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.","CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123314","json":"https://secwatch.observer/filing/0000950170-24-123314.json","markdown":"https://secwatch.observer/filing/0000950170-24-123314.md","text":"https://secwatch.observer/filing/0000950170-24-123314.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/0000950170-24-123314-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501989/000095017024123314/ctmx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:29:29.859273+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}